Bortezomib como alternativa en el tratamiento de pacientes con gammapatías malignas / Bortezomib as an alternative in the treatment of patients with malignant gammopathy

Objetivo: Describir el uso de bortezomib en un hospital comarcal como alternativa en el tratamiento de gammapatías malignas. Métodos: Análisis retrospectivo de los pacientes tratados con bortezomib en nuestro hospital desde noviembre de 2005 hasta octubre de 2007. A partir de la revisión de las historias clínicas de los pacientes se recogieron los datos correspondientes al diagnóstico, tratamientos previos a bortezomib, fecha de la última progresión de la enfermedad, número de ciclos de bortezomib, respuesta a éste, super vivencia global y libre de progresión, complicaciones y efectos secundarios. Resultados: El 47% de los pacientes estudiados eran varones (5/12), con una mediana de edad de 67 años (rango, 40-81 años). El diagnóstico principal fue mieloma múltiple, solo o asociado a plasmocitoma. El inicio con bortezomib coincidió con la última progresión de la enfermedad en el 83% de los pacientes (10/12). El 50% completó 7-8 ciclos con bortezomib. Se obtuvo respuesta en el 58% de los pacientes (7/12), alcanzándose criterios de respuesta parcial en el 33% (4/12) y respuesta completa en el 25% (3/12). Las reacciones adversas más frecuentes fueron neuropatía y toxicidad gastrointestinal, y supuso la suspensión del tratamiento en el 50% de los casos. Conclusiones: Según los resultados obtenidos, bortezomib es una buena alternativa en el tratamiento de las gammapatías malignas, sobre todo en el caso de plasmocitomas (AU)

Objective: To describe the use of bortezomib in a district hospital as an alternative in the treatment of malignant gammopathy. Methods: A retrospective analysis was carried out on patients treated with bortezomib in our hospital between November 2005 and October 2007. The patients’ medical histories were used to obtain data regarding diagnosis, treatments prior to bortezomib, date of the last disease progression, number of bortezomib courses, response to bortezomib, overall and event free survival. Results: 47% of the patients studied were male (5/12). The medianage was 67, (age range between 40 and 81). The main diagnosis was multiple myeloma on its own or associated with plasmocytoma. Bortezomib initiation coincided with the last disease progression in 83%of patients (10/12). 50% of the patients completed 7-8 courses of bortezomib. Response was seen in 58% of the patients (7/12), partial response in 33% of them (4/12) and complete response in 25%(3/12). The most common adverse reactions were neuropathy and gastrointestinal toxicity which required treatment to be discontinued in 50% of cases. Conclusions: According to the results obtained, bortezomib is a good alternative in the treatment of malignant gammopathy, above all in the case of plasmocytomas (AU)

[Bortezomib as an alternative in the treatment of patients with malignant gammopathy]. / Bortezomib como alternativa en el tratamiento de pacientes con gammapatías malignas.

OBJECTIVE: To describe the use of bortezomib in a district hospital as an alternative in the treatment of malignant gammopathy. METHODS: A retrospective analysis was carried out on patients treated with bortezomib in our hospital between November 2005 and October 2007. The patients' medical histories were used to obtain data regarding diagnosis, treatments prior to bortezomib, date of the last disease progression, number of bortezomib courses, response to bortezomib, overall and event free survival. RESULTS: 47% of the patients studied were male (5/12). The median age was 67, (age range between 40 and 81). The main diagnosis was multiple myeloma on its own or associated with plasmocytoma. Bortezomib initiation coincided with the last disease progression in 83% of patients (10/12). 50% of the patients completed 7-8 courses of bortezomib. Response was seen in 58% of the patients (7/12), partial response in 33% of them (4/12) and complete response in 25% (3/12). The most common adverse reactions were neuropathy and gastrointestinal toxicity which required treatment to be discontinued in 50% of cases. CONCLUSIONS: According to the results obtained, bortezomib is a good alternative in the treatment of malignant gammopathy, above all in the case of plasmocytomas.

[Systemic mastocytosis and secondary acute myeloid leukemia]. / Mastocitosis sistémica y leucemia mieloide aguda secundaria.

Systemic mast cell disease (SMCD) is an idiopathic disorder in which mast cells proliferate and accumulate in various organs including the skin, bone marrow, liver, spleen and lymph nodes. SMCD is regarded as a myeloproliferative disorder for any authors. Associated hematologic disorders can be found in up to one third of patients with SMCD. It may be due to the apparent close relationship between the mast cell and the myeloid cell.

Mastocitosis sistémica y leucemia mieloide aguda secundaria / Acute myeloid leukemia secondary a systemic mastocitosis

La mastocitosis sistémica es una enfermedad en la cual los mastocitos proliferan y se acumulan en distintos tejidos como la piel, médula ósea, hígado, bazo y ganglios linfáticos. Algunos autores la consideran como un síndrome mieloproliferativo. Una tercera parte de los pacientes desarrollan otras neoplasias hematológicas, apoyando el origen mieloide del mastocito (AU)